SEHK:1349

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical

Market Cap

HK$17.5b

Last Updated

2021/06/21 16:33 UTC

Data Sources

Company Financials

Executive Summary

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells bio-pharmaceutical products. More Details

Risk Analysis

High level of non-cash earnings



Snowflake Analysis

Flawless balance sheet with poor track record.

Share Price & News

How has Shanghai Fudan-Zhangjiang Bio-Pharmaceutical's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 1349 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: 1349's weekly volatility (7%) has been stable over the past year.


Market Performance


7 Day Return

1.8%

1349

-4.2%

HK Pharmaceuticals

-1.6%

HK Market


1 Year Return

-8.4%

1349

9.7%

HK Pharmaceuticals

20.4%

HK Market

Return vs Industry: 1349 underperformed the Hong Kong Pharmaceuticals industry which returned 8.4% over the past year.

Return vs Market: 1349 underperformed the Hong Kong Market which returned 21.5% over the past year.


Shareholder returns

1349IndustryMarket
7 Day1.8%-4.2%-1.6%
30 Day1.2%-0.8%-0.9%
90 Day19.5%10.4%0.2%
1 Year-7.4%-8.4%11.2%9.7%24.6%20.4%
3 Year43.2%37.7%-13.1%-18.2%11.3%-0.7%
5 Year-23.7%-28.2%107.3%87.0%58.3%31.1%

Long-Term Price Volatility Vs. Market

How volatile is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical undervalued compared to its fair value and its price relative to the market?

23.26x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 1349 (HK$5.15) is trading above our estimate of fair value (HK$1.39)

Significantly Below Fair Value: 1349 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 1349 is poor value based on its PE Ratio (23.3x) compared to the Hong Kong Pharmaceuticals industry average (13.4x).

PE vs Market: 1349 is poor value based on its PE Ratio (23.3x) compared to the Hong Kong market (11.5x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 1349's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 1349 is overvalued based on its PB Ratio (2.2x) compared to the HK Pharmaceuticals industry average (1.3x).


Future Growth

How is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

16.3%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Shanghai Fudan-Zhangjiang Bio-Pharmaceutical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Shanghai Fudan-Zhangjiang Bio-Pharmaceutical performed over the past 5 years?

10.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 1349 has a high level of non-cash earnings.

Growing Profit Margin: 1349's current net profit margins (20.3%) are lower than last year (20.8%).


Past Earnings Growth Analysis

Earnings Trend: 1349's earnings have grown by 10.3% per year over the past 5 years.

Accelerating Growth: 1349's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 1349 had negative earnings growth (-7.9%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (9.2%).


Return on Equity

High ROE: 1349's Return on Equity (9.3%) is considered low.


Financial Health

How is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical's financial position?


Financial Position Analysis

Short Term Liabilities: 1349's short term assets (CN¥1.9B) exceed its short term liabilities (CN¥338.1M).

Long Term Liabilities: 1349's short term assets (CN¥1.9B) exceed its long term liabilities (CN¥58.7M).


Debt to Equity History and Analysis

Debt Level: 1349 is debt free.

Reducing Debt: 1349 has no debt compared to 5 years ago when its debt to equity ratio was 11.5%.

Debt Coverage: 1349 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 1349 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical current dividend yield, its reliability and sustainability?

1.17%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 1349's dividend (1.17%) isn’t notable compared to the bottom 25% of dividend payers in the Hong Kong market (1.9%).

High Dividend: 1349's dividend (1.17%) is low compared to the top 25% of dividend payers in the Hong Kong market (6.06%).


Stability and Growth of Payments

Stable Dividend: 1349 has been paying a dividend for less than 10 years and during this time payments have been volatile.

Growing Dividend: 1349 has only been paying a dividend for 6 years, and since then payments have not increased.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (27.2%), 1349's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

15.4yrs

Average management tenure


CEO

Hai Bo Wang (61 yo)

no data

Tenure

CN¥3,276,000

Compensation

Mr. Haibo Bo Wang co-founded Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. in November 1996 and serves as its Chairman of the Board and General Manager. Mr. Wang serves as Chairman of the Board and...


CEO Compensation Analysis

Compensation vs Market: Hai Bo's total compensation ($USD507.66K) is about average for companies of similar size in the Hong Kong market ($USD647.16K).

Compensation vs Earnings: Hai Bo's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: 1349's management team is seasoned and experienced (15.4 years average tenure).


Board Members

Experienced Board: 1349's board of directors are considered experienced (7.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
  • Ticker: 1349
  • Exchange: SEHK
  • Founded: 1996
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: HK$17.456b
  • Shares outstanding: 1.04b
  • Website: https://www.fd-zj.com

Number of Employees


Location

  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
  • Zhangjiang Hi-Tech Park
  • No. 308 Cailun Road
  • Shanghai
  • 201210
  • China

Listings


Biography

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells bio-pharmaceutical products. It offers genetic engineering platform dru...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/06/21 16:33
End of Day Share Price2021/06/21 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.